Bupropion for weight reduction
Authors: Gadde, Kishore M; Xiong, Glen L
Source: Expert Review of Neurotherapeutics, Volume 7, Number 1, January 2007 , pp. 17-24(8)
Publisher: Expert Reviews
Abstract:
Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients. The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.Keywords: antiobesity drugs; bupropion; obesity; weight loss
Document Type: Research article
DOI: http://dx.doi.org/10.1586/14737175.7.1.17
Publication date: 2007-01-01
- Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Information for Librarians
- Free Trials
- ingentaconnect is not responsible for the content or availability of external websites
- In this: publication
- By this: publisher
- In this Subject: Pharmacology , Neuropsychology
- By this author: Gadde, Kishore M ; Xiong, Glen L

Shopping cart
Receive new issue alert
Get Permissions